Effects of metformin plus gliclazide versus metformin plus glimepiride, which are anti diabetic drugs, on heart disease risk in patients with diabetes.
- Conditions
- Health Condition 1: E11- Type 2 diabetes mellitus
- Registration Number
- CTRI/2020/07/026850
- Lead Sponsor
- Dr Salman H Rizvi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Individuals more than 18 yrs of age.
2. Patients who had failed on monotherapy with metformin (1000 mg/day).
3. HbA1c >= 6.5%.
4. FPG >126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 hours.
5. PPPG >200 mg/dl (11.1 mmol/l) two hours after meals.
1. Those patients requiring change in dose as per treating physician during study period will be excluded from the study.
2. Patient with renal disease.
3. Patient on insulin 6 months prior to screening.
4. Patients with any acute or chronic complication of diabetes mellitus.
5. Patients with infection 4 wks. prior to screening.
6. Patients on parenteral glucocorticoids, growth hormone.
7. Patient suffering from active or chronic hepatic disease.
8. Pregnant/ lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method